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Summary statement: A meta-analysis of vitrectomy for diabetic macular edema found no significant difference in 
visual outcome compared to laser or observation. Retinal thickness was better than with laser/observation at 6 
months, but this benefit had reversed by 12 months. Intraoperative retinal breaks occurred in 7.1%, and 
postoperative retinal detachment in 1.2% 
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Abstract 
Purpose. To assess the risk and benefit of pars plana vitrectomy for diabetic macular 
edema (DME). 
Methods. We conducted a systematic literature review using PubMed, EMBASE, Web 
of Science, and Cochrane Central Database of Controlled Trials until September 2014. 
The population was patients with DME, intervention vitrectomy, comparator macular 
laser or observation, and efficacy outcome visual acuity and central retinal thickness 
(CRT). Safety outcomes were intra- and postoperative surgical complications. The 
efficacy meta-analysis included only randomized controlled trials. The safety analysis 
included prospective, retrospective, controlled and uncontrolled studies. 
Results. Five studies were eligible for the efficacy meta-analysis (n = 127 eyes) and 40 
for the safety analysis (n = 1,562 eyes).  Combining follow up intervals from 6 to 12 
months, the meta-analysis found a non-significant 2 letter visual acuity difference 
favoring vitrectomy, and a significant 102 micron greater reduction in CRT favoring 
vitrectomy, but a post-hoc subgroup analysis found that a 6 month CRT benefit reversed 
by 12 months. The most frequent complications were retinal break (7.1%), elevated 
intraocular pressure (5.2%), epiretinal membrane (3.3%), and vitreous hemorrhage 
(2.4%). Cataract developed in 68.6% of 121 phakic eyes. 
Conclusions. Vitrectomy produces structural and functional improvements in select 
eyes with DME, but the visual gains are not significantly better than with laser or 
observation. No major safety concerns were identified. 
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Introduction 
Diabetic macular edema (DME) is a leading cause of visual loss in developed nations,1, 
2 and as the population with diabetes expands,3 the burden of DME will increase. For 
many years the standard therapy for DME has been focal macular photocoagulation 
laser. The Early Treatment of Diabetic Retinopathy Study (ETDRS) established that 
laser approximately halves the risk of moderate vision loss in patients with clinically 
significant macular edema.4 More recently, several randomized controlled trials (RCTs) 
have demonstrated the safety and efficacy of intravitreal steroid injections and 
implants.5-9 Vascular endothelial growth factor (VEGF), by increasing vascular 
permeability, plays an important role in the pathogenesis of DME.10, 11 Studies 
investigating the intravitreal use of the anti-VEGF agents ranibizumab,12-16 
aflibercept,2, 17 and bevacizumab18 have also shown favorable results.19 
 
There are a number of clinical studies suggesting that an attached vitreous may 
adversely affect the clinical course of DME, or possibly contribute to its pathogenesis. 
Sivaprasad et al found that posterior vitreous detachment (PVD) was less common in 
eyes with DME, and that vitreous attachment appeared to reduce the benefit of 
intravitreal steroid therapy.20 A synthesis of the literature by Jackson et al found that 
some degree of vitreomacular traction (VMT) was present in 12% of eyes with DME, 
and up to 24% in surgical series.21 Vitreomacular traction may aggravate any 
underlying tendency for DME, and if severe, VMT can cause macular edema in its own 
right. It therefore seems reasonable to assume that relief of VMT would be beneficial. 
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Several authors have advocated the use of pars plana vitrectomy (PPV) to treat DME. 
Whilst PPV is well established for the treatment of persistent vitreous hemorrhage22 
and tractional retinal detachment,23, 24 its use as a treatment for DME has not been 
supported by large randomized controlled trials (RCTs). 
 
Laboratory studies provide a theoretical basis to support the use of PPV. Several animal 
studies25-27 and some human studies28 reported that PPV increases vitreous oxygenation 
in the context of ischemia, and increased oxygen tension is likely to reduce VEGF. It 
has been estimated that vitreous viscosity is 300 to 2000 times greater than aqueous,29 
and following vitrectomy diffusion coefficients of intravitreal molecules, including 
VEGF, should increase by a similar magnitude.30 Therefore, following PPV, VEGF and 
other pro-inflammatory cytokines would be expected to diffuse away from the macula 
more easily.31 Conversely, the post-vitrectomy decrease in the viscosity of the vitreous 
cavity has the possible disadvantage of interfering with intraocular pharmacokinetics 
and reducing the half-life of intravitreal drugs.32 
 
In the absence of large RCTs of PPV for DME we aimed to undertake a systematic 
review and meta-analysis to assess if PPV is an appropriate surgical intervention. 
Specifically, we aimed to determine the benefit of PPV in terms of the mean change in 
visual acuity (VA) and reduction in optical coherence tomography (OCT) central retinal 
thickness (CRT), and the risk in terms of intra- and postoperative complications. An 
analysis of risk and benefit is particularly important in the context of new intravitreal 
drug treatments that have proven efficacy and favorable safety profiles - interventions 
that do not expose patients to the risks of PPV.  
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Methods 
Study design, population, intervention, comparison and outcome 
We aimed to estimate the risk and benefit of PPV for DME. To estimate the potential 
benefit of PPV we used a meta-analysis of efficacy outcomes, selecting only RCTs. To 
estimate the risks of PPV, in terms of surgical complications, we undertook a systematic 
review, to encompass a wider range of literature and increase the likelihood of detecting 
rare events. The population was patients with DME, the  intervention was PPV, and the 
comparison was traditional standard care,4 namely focal macular photocoagulation 
laser or observation. The two main efficacy outcomes were visual acuity (VA), and 
optical coherence tomography (OCT) central retinal thickness (CRT). Safety outcomes 
included all reported intra- or postoperative surgical complications, or other adverse 
events attributed to PPV or local or general anesthesia. The study protocol was 
registered with the international prospective register of systematic reviews (registration 
number CRD42014013646, National Institute of Health Research Centre for Reviews 
and Dissemination, University of York, UK) and conducted in accordance with 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidance (http://www.prisma-statement.org/, accessed 21 January 2015). 
 
Eligibility  
To be eligible for the meta-analysis RCTs had to recruit patients with DME, and 
compare PPV to traditional standard care (observation or macular photocoagulation 
laser), for the treatment of DME. Outcome data had to include change in VA and change 
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in CRT at least 6 months after enrolment, and safety at any time point. The data had to 
be of sufficient quality, in terms of clear eligibility, defined efficacy and safety 
outcomes, and data completeness, and in particular studies had to report any 
complications that occurred, or state that there were none.  Only English, French and 
German language articles in peer-reviewed journals were eligible. Studies that failed to 
provide pre- and post-operative VA were excluded, as were those appearing as abstract 
only, and studies where patients received adjunctive therapy such as intravitreal steroids 
and anti-VEGF drugs, as these could confound the analysis of vitrectomy versus 
laser/observation. Editorials, expert opinions, and articles in non-peer reviewed 
journals were excluded. Articles using intravitreal vital stains to assist with peeling of 
the internal limiting membrane (ILM) were not excluded.33-36 Similar eligibility criteria 
were applied to the safety analysis, except that studies did not need to be RCTs or have 
a control group, the minimum VA follow up did not apply, and they need not report 
CRT. Prospective, retrospective, controlled and uncontrolled studies, including case 
reports, were eligible for the safety analysis.  
 
Literature review 
An Ovid MEDLINE database search from 1946 to 23 September 2014 was undertaken 
using Boolean operators with the following keywords (and corresponding MESH 
headings if they were available): vitrectomy; diab*; macula*; oedema or edema; 
maculopathy; vitreomacular traction; vitreomacular adhesion; taut posterior hyaloid. 
The search was not restricted by adding terms such as adverse events, complications, 
or safety, but rather each eligible article was reviewed for safety data. Searches were 
repeated using EMBASE™ (Ovid), and the Cochrane Central Database of Controlled 
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Trials (CENTRAL, Cochrane library). An example search is shown in eAppendix 1 
(see Supplement).  
 
The retrieved abstracts were then reviewed by two senior retinal experts (TJ, EP) who 
selected articles for full review if they appeared to meet the eligibility criteria. Further 
articles were identified in the bibliographies of retrieved articles. Where necessary, 
authors were contacted to obtain unpublished raw data from RCTs.  
 
Data extraction 
Three independent reviewers (FG, AA, EN) entered data from each article into an 
electronic data capture form. Any discrepancy was resolved by consensus or, if 
necessary, by arbitration of a senior retinal specialist (TJ). The protocol for data 
collection included the following information for each article: 1) general information 
about the study (aim, summary, key findings); 2) methodological details (study design, 
study population, entry criteria, methods, study period); 3) primary and secondary 
outcomes; 4) presenting and final VA; 5) whether or not eyes underwent peeling of the 
ILM at the time of PPV; 6) safety outcomes (adverse events and serious adverse events, 
including surgical complications and reoperations).   
 
Assessment of bias 
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The risk of bias was assessed using the Cochrane Risk of Bias Assessment tool which 
grades risk of bias as low, unclear or high risk. Seven domains of risk where assessed 
including assessments for selection bias, performance bias, detection bias, attrition bias 
and reporting bias. 
 
Data analysis 
To analyse visual outcome across studies the mean VA data were converted to 
logarithm of the minimum angle of resolution (LogMAR) units.37 Counting fingers 
vision was assigned a LogMAR acuity of 1.6, hand movements 1.9, light perception 
2.2, and no light perception 2.5.38-40 Meta-analysis was used to pool comparisons of the 
mean change in LogMAR VA and change in CRT comparing PPV and control 
(observation or laser). The fixed effect method with inverse variance weighting was 
used. Statistical analysis was performed using RevMan 5.2 available from the Cochrane 
Collaboration.41  Safety data were pooled across all studies, including non-RCTs.  
 
Results 
Meta-analysis of efficacy: 
Six RCTs were identified that provided mean change in LogMAR VA and mean change 
in retinal thickness, comparing patients having undergone PPV with controls.42-47  One 
study was excluded, as it was not possible to obtain raw data or summary statistics for 
the outcomes in question, despite contacting the author (eAppendix 2, see 
supplement).47 Additional, anonymous participant-level data were obtained from two 
study authors, such that their reports could be included in the meta-analysis.45, 46  Of 
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the five RCTs included, four used a laser control group42, 43, 45, 46 and one used an 
untreated control group44. We identified possible duplicate reporting in two studies43, 
44, but concluded these were different populations given the different eligibility criteria 
and control groups.  Follow up duration was 6 months in 3 studies42, 44, 46 and 12 
months45, 46 in 2 (one study reported both outcomes46) (Table 1).  One study46 reported 
results at 6 and 12 months, where 5 patients were double counted for the LogMAR 
results and 6 patients for the CRT.  Sensitivity analysis was performed to test the effect 
on the results by excluding the 6 month or 12 month outcome.  This resulted in similar 
magnitude and precision of results. We preferred to report the combined results (at 6 
and 12 months) due to the greater sample size. This summarizing error was considered 
acceptable as sensitivity analysis testing showed it did not affect the conclusion. 
 
All RCTs appeared to be at low risk of reporting bias (Figures 1A and 1B).  It is not 
possible to effectively mask patients to the intervention, vitrectomy, observation or 
control, and as such all studies are at risk of introducing performance bias. Detection 
bias may have been minimized by using masked assessors for VA outcome collection, 
although only 2 out of 5 studies explicitly stated doing this.44, 48 It was felt that the 
collection of automated OCT central retinal thickness data was unlikely to introduce 
bias whether masked assessors were used or not. Randomization methodology and 
allocation concealment were not always explicitly reported across the trials (see 
eAppendix 3 in the Supplement).
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Table 1. Randomized controlled study characteristics included in the meta-analysis, showing visual acuity and central retinal thickness before and after pars plana 
vitrectomy 
  Thomas 2005 Yanyali 2005 Yanyali 2006 Patel 2006 Kumar 2007 
Patient 
population 
33 eyes of 33 patients 
with DME, VA of 0.3 
logMAR or worse, 
after one or more 
macular laser 
treatments 
24 eyes of 12 patients 
with DME in both eyes. 
One eye used as 
control. 
20 eyes of 10 patients 
with DME in both eyes. 
One eye used as contol. 
Patients were 
unresponsive to grid 
laser photocoagulation 
12 eyes from 12 patients with 
persistent clinically significant 
DME despite previous macular 
laser. 
24 eyes of 24 
patients with 
diffuse DME.  
Males (%) 70 41.7 40 58 91.7 
Mean follow-up 
period (months) 
12 6 12 6 and 12 6 
Intervention PPV + ILM peeling PPV + ILM peeling PPV + ILM peeling Standard three-port PPV with 
elevation and the removal of 
the posterior vitreous 
cortex (no ILM peeling) 
PPV + ILM peeling 
Treated eyes 
(number) 
15 12 10 7 12 
Mean age (years) 64.3 64.4 61.5 63 (all) 57.25 
LogMAR VA ± 1SD 
before (Snellen) 
0.67 ± 0.30 
(20/94) 
0.75 ± 0.40 
(20/112) 
0.72 ± 0.43 
(20/105) 
0.55 ± 0.18 
(20/71) 
1.11 ± 0.09 
(20/258) 
LogMAR  VA ± 1SD 
after (Snellen) 
0.71 ± 0.33 
(20/103) 
0.54 ± 0.40 
(20/69) 
0.55 ± 0.45 
(20/71) 
0.5 ± 0.22 (20/63) (6 eyes/6 
months)  
0.57  ± 0.18 (20/74) (6 eyes/12 
months) 
0.92 ± 0.10 
(20/166) 
CRT ± 1SD before 
(μl) 
426.2 ± 111.2 439.3 ± 102.0 391.3 ± 91.6 375.3 ±144.8 567.5 ± 147.9 
CRT ± 1SD after (μl) 347.1 ± 202.9 219.8 ± 60.6 225.5 ± 49.5 318.2 ± 114.8 (6 eyes/6 
months) 
266.6 ± 69.4 
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334.17 ± 112.0 (6 eyes/12 
months) 
Control  Macular laser Modified grid laser 
photocoagulation 
Untreated controls Laser Modified grid laser 
photocoagulation 
Control eyes 
(number) 
18 12 10 8 12 
Mean age (years) 64 64 62 63 (all) 57 
LogMAR VA ± 1SD 
before (Snellen) 
0.62 ± 0.23 
(20/83) 
0.59 ± 0.26 
(20/78) 
0.44 ± 0.44 
(20/55) 
0.50 ± 0.25 
(20/63) 
1.07 ± 0.06 
(20/235) 
LogMAR  VA ± 1SD 
after (Snellen) 
0.57 ± 0.32 
(20/74) 
0.50 ± 0.26 
(20/63) 
0.60 ±0.56 
(20/80) 
0.42 ± 0.22 (20/53) (8 eyes/6 
months) 
0.31 ±0.13 (20/40) (6 eyes/12 
months) 
0.97 ± 0.09 
(20/186) 
CRT ± 1SD before 
(μl) 
440.3 ± 172.8 407.1 ± 96.0 356.2 ± 140.1 404.5 ± 145.8 463.6 ± 92.4 
CRT ± 1SD after (μl) 330.0 ± 117.7 378.5 ± 135.6 318.4 ± 111.1 320.63 ± 114.0 (8 eyes/6 
months) 
308.2 ± 123.1 (6 eyes/12 
months) 
357.0 ± 77.21 
 
Footnote: VA: visual acuity; CRT: central retinal thickness; DME: diabetic macular edema; ILM peel: internal limiting membrane peeling; PPV: pars plana 
vitrectomy; SD: standard deviation; VA: visual acuity.  
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Figure 1. Risk of bias summary and graph. 
 
 
Figure 1 illustrates the risk of bias summary (A) and the risk of bias graph (B). The 
review is based on the authors' judgements about each risk of bias item for each 
included study. The risk of bias in each paper was evaluated for across seven domains. 
Each domain was rated as either Low Risk, Unclear Risk or High Risk of introducing 
bias.  
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Abbreviations: + low risk; ? unclear risk; - high risk. 
 
Figure 2 shows a forest plot of the vision outcome (mean change in VA in LogMAR 
units) from the meta-analysis of the five RCTs, comparing PPV with control. Overall 
there was a 2 letter (0.04 logMAR units) difference favoring PPV over control but this 
was not significant (95% confidence interval [CI] -0.02 to 0.1 logMAR units, p=0.18). 
 
As part of the iterative process and in accordance with PRISMA guidance, the original 
analysis protocol was adapted to accommodate the variability in the follow up interval 
reported (6 or 12 months) and control group (observation or laser). Specifically, we 
undertook a post-hoc analysis of the main efficacy outcome measures (change in mean 
VA and CRT) in three subgroups: 1) studies reporting outcomes at 6 months with laser 
control; 2) studies reporting at 12 months with laser control; and 3) studies reporting at 
12 months with untreated controls. In the laser controlled studies, using mean VA at 6 
months there was an almost significant (p=0.05) benefit from vitrectomy compared to 
laser, however this reversed at 12 months, with an almost significant result favoring 
laser (p=0.07). The subgroup analyses are shown in Figure 2. Within each subgroup the 
results were similar, however on combining all 3 subgroups there was moderate 
heterogeneity (I2 of 60%). 
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Figure 2. Meta-analysis of vision outcome comparing pars plana vitrectomy to standard care 
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Figure 3. Meta-analysis of change in optimal coherence tomography macular thickness comparing pars plana vitrectomy to standard care 
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Figure 2 shows a meta-analysis of vision outcome (change in mean logarithm of the minimum angle of visual acuity), comparing pars plana 
vitrectomy to standard care (observation or macular laser). The overall analysis of the five RCTs showed a better visual outcome in the vitrectomy 
group, but this was not quite significant and there was heterogeneity amongst the trials.  
Abbreviations: CI = confidence interval; IV = Inverse variance method used; Fixed= Fixed effect model used; SD = standard deviation. 
 
Figure 3 presents a meta-analysis of change in optical coherence tomography macular thickness, comparing pars plana vitrectomy or standard 
care (observation or macular laser). The overall analysis showed that vitrectomy resulted in a significantly greater reduction in macular thickness 
than standard care. 
Abbreviations: CI = confidence interval; IV = Inverse variance method used; Fixed= Fixed effect model used; SD = standard deviation. 
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Figure 3 presents a forest plot of the meta-analysis of the same five RCTs, with respect 
to change in CRT. Overall there was a significant, 102 m (95% CI 61 to 144m, 
p<0.00001) greater reduction in macular thickness in the pooled vitrectomy group 
compared with the control group (I2 of 78%). However, as can be seen in Figure 3, the 
subgroup analysis suggested that the advantage of PPV over laser at 6 months was not 
evident at 12 months.   
 
Safety:  
A total of 425 abstracts were retrieved. Of these 106 potentially eligible articles were 
reviewed in full, of which 40 were eligible for the safety analysis. Although the 
literature search extended back to 1946, the first eligible report was published in 1992,3 
and 38 of 40 were published after 2000 (eAppendix 4, see supplement).  
 
In 40 studies, intra- and postoperative complications were reported (Table 2).3, 42-44, 46, 
48-82 The most frequent intraoperative surgical complications were peripheral retinal 
break (7.08% of 1,469 eyes), iatrogenic tears (0.68% of 1,469 eyes), and focal, petechial 
spontaneously resolving retinal hemorrhage (0.34% of 1,469 eyes). The most frequent 
postoperative complications were raised intraocular pressure (5.19% of 1,562 eyes), 
epiretinal membrane (3.27% of 1,562 eyes), vitreous hemorrhage (2.43% of 1,562 
eyes), neovascular glaucoma (1.60% of 1,562 eyes), glaucoma (1.41% of 1,562 eyes), 
macular hard exudates (1.34% of 1562 eyes) and retinal detachment (1.22% of 1,562 
eyes). 
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Table 2. Intra- and postoperative complications3,42-44,46,48-82 
Intra-operative complications 
Number of 
eyes 
Number of 
eyes 
affected 
Eyes 
affected (%) 
Peripheral retinal break 1469 104 7.08% 
Iatrogenic tears 1469 10 0.68% 
Focal, petechial, spontaneously resolving retinal 
hemorrhage 1469 5 0.34% 
Retinal detachment 1469 2 0.14% 
Entry site break 1469 1 0.07% 
    
post-operative complications    
Cataract* 1562 40 2.56% 
Cataract surgery 1562 19 47.50% 
Intraocular pressure 1562 81 5.19% 
Epiretinal membrane 1562 51 3.27% 
Vitreous hemorrhage 1562 38 2.43% 
Neovascular glaucoma 1562 25 1.60% 
Glaucoma 1562 22 1.41% 
Hard exudate deposits in the center of the 
macula 1562 21 1.34% 
Retinal detachment 1562 19 1.22% 
Mild progression of nuclear sclerosis 1562 12 0.77% 
Rhematogenous retinal detachment 1562 10 0.64% 
Cystoid macular edema 1562 6 0.38% 
Macular retinal pigment epithelium 
abnormalities 1562 5 0.32% 
Ocular hypertension 1562 4 0.26% 
Neovascularisation of the angle 1562 3 0.19% 
Secondary Glaucoma 1562 3 0.19% 
APE atrophy of the macula 1562 3 0.19% 
Unusual refex of the retinal surface 1562 3 0.19% 
Ischemic optic neuropathy 1562 3 0.19% 
Endophthalmitis 1562 3 0.19% 
Lipid deposit in the centre of the macula 1562 3 0.19% 
Central retinal vein occlusion 1562 2 0.13% 
Full-thickness macular hole 1562 1 0.06% 
Dissociated optic nerve fiber layer appearance 1562 1 0.06% 
Posterior vitreous detachment 1562 1 0.06% 
Lamellar macular hole 1562 1 0.06% 
Choroidal neovascularization 1562 1 0.06% 
Deterioration of existing cataract 1562 1 0.06% 
Partial thickness macular hole 1562 1 0.06% 
Retinal hemorrhage 1562 1 0.06% 
*Cataract developed in 68.6% of 121 phakic eyes 
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The rate of post-vitrectomy cataract was not reliably reported and many reports did not 
detail the proportion of phakic eyes. Cataract was reported to develop in only 40 of 
1,562 eyes (2.56%), of which 47.5% (19 of 40 eyes) underwent subsequent cataract 
surgery. Four studies provided the post-vitrectomy cataract rate in 121 phakic eyes, and 
83 (68.6%) of these eyes developed cataract over a mean of 31.0 months.57, 65, 67, 70 
 
A post hoc safety analysis was undertaken using the data from the RCTs included in 
the efficacy meta-analysis, to assess if the complication rates differed from those 
reported in the main safety analysis (which included uncontrolled and retrospective 
studies). The complication rates appeared similar in the 46 participants with detailed 
safety reporting, in that the most common complication was progression of nuclear 
sclerosis (23.9%) followed by raised intraocular pressure (6.5%). The only other 
complication reported was rhegmantogenous retinal detachment in one patient 
(2.1%).42-44, 46  
  
Discussion 
Our meta-analysis of RCTs suggests that the visual benefits following vitrectomy for 
DME were not significantly better than those achieved using conventional management 
with laser and observation. The RCTs indicated that PPV was associated with a 
significantly greater reduction in macular thickness than laser and observation, but there 
was heterogeneity in this overall result, and our subgroup analysis may be more 
informative. This showed a trend for better OCT results than with laser at 6 months, 
but this trend had reversed by 12 months.  
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The VA gain in the RCTs was equivalent to 2 ETDRS letters (0.04 LogMAR). The 
Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study randomized 
patients with DME to receive ranibizumab, macular laser, or both.14 In the group 
receiving only ranibizumab, vision improved by an average of 7.4 letters at 6 months. 
Another RCT compared ranibizumab alone, and in combination with macular laser, and 
reported a mean gain of 6.1 letters at 12 months in the group that only received 
ranibizumab.15 Yet another study showed a 5.8 letter gain following ranibizumab and 
deferred laser.16 As such the PPV RCT results do not compare favorably with those of 
anti-VEGF therapy in terms of the mean VA change (or in relation to the comparison 
with a laser control group). However, ddirect comparison between the anti-VEGF 
studies and our meta-analysis is difficult for several reasons. Key amongst these is that 
vitrectomy is often reserved for patients who have failed other treatments, whereas anti-
VEGF agents are often used as a first-line treatment. Ideally, there would be RCTs 
directly comparing PPV and anti-VEGF treatments.  
 
No major safety concerns were identified. Retinal breaks were the most common 
complication. A database study of 8,257 PPVs also found that retinal breaks were the 
most common intraoperative complication.83 In the subset of eyes undergoing epiretinal 
membrane surgery, a PPV of similar complexity, iatrogenic retinal breaks occurred in 
3.0% of cases, whereas the present series incorporated studies that used somewhat 
varying terminology, with those describing ‘peripheral retinal breaks’ averaging a 7.1% 
rate, and those reporting ‘iatrogenic tears’ averaging 0.7%.  Retinal detachment 
occurred in 1.5% of the epiretinal membrane cases, compared with 1.2% in the present 
analysis. The incidence of post-vitrectomy hemorrhage and neovascular glaucoma were 
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higher in the present series, consistent with an underlying diagnosis of diabetes. 
Although the safety of PPV for DME appears comparable to other studies of PPV, the 
complication rates are higher than those seen following intravitreal anti-VEGF 
injections for DME.13, 15, 16  
   
The main strength of the present meta-analysis is that it provides a pooled estimate of 
treatment effect across several RCTs, and the safety analysis considers an even larger 
pool of patients that may be better able to detect rare events. There is a risk that 
publication or reporting bias may favor the selection of reports describing positive 
surgical outcomes.84, 85 Also, post-vitrectomy lens changes may be a confounding 
variable. It was not possible to determine the lens status in many studies, or to reliably 
determine the proportion of eyes that underwent cataract surgery. It is well known that 
PPV causes cataract and this is likely to reduce the mean visual gain, and this is possibly 
suggested by the worse VA outcome at 12 months compared to 6 months, as shown in 
Figure 2 (this would not however explain a worsening of the OCT outcome over this 
timeframe). Conversely, removal of preexisting lens opacity during initial combined 
phakovitrectomy, or subsequently as a result of post-vitrectomy cataract, will tend to 
improve the mean VA of the PPV group.  Although laser or observation remain the 
standard of care for many patient, anti-VEGF therapy is now emerging as a standard of 
care for many other patients. Our results suggest that PPV is not superior to laser or 
observation, and the pivotal anti-VEGF trials in turn show that anti-VEGF treatment is 
superior to laser; this might appear to indicate that anti-VEGF therapy is superior to 
PPV, that analysis requires direct comparison of PPV versus anti-VEGF therapy, and 
is not proven by our analysis. 
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Another intrinsic difficulty of studies involving PPV is that masking is not possible, as 
sham surgery would not be practical. However most of the RCTs provided relatively 
robust VA assessment and lack of masking is unlikely to materially influence CRT 
measurement, which relies on automated computer software analysis.  
 
Interventional case series recruit patients in whom surgery is considered clinically 
reasonable, and those with milder disease may have been excluded.86 Therefore the 
results may not be representative of all patients with DME, or comparable with studies 
investigating intravitreal injections. Also, even if the overall functional benefit was no 
better than macular laser, it is possible that a subgroup of patients with DME and 
significant vitreomacular traction may benefit from PPV. Vitreomacular traction or taut 
posterior hyaloid is reported to be present in 17% of DME cases undergoing PPV.21  
 
In summary, this study found that PPV produced both structural and functional benefit 
in eyes with DME, but the functional benefit was not significantly better than that 
obtained using macular laser, and the structural benefits appeared to decline, or possibly 
reverse, with time. Like previous reviews,21 we identified a lack of high quality 
evidence, and the need for large RCTs comparing PPV to the latest gold standard, in 
particular intravitreal anti-VEGF drugs. Given the favorable results with these newer 
treatments, the need to justify PPV becomes even greater. 
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Appendix 1 Search Strategy 
Illustrative literature search using OvidSP (EMBASE) to retrieve studies of pars plana 
vitrectomy for the treatment of diabetic macular edema. 
 Searches Results 
1 edema.mp. or edema/ 225,844 
 
2 oedema.mp. [mp=title, abstract, subject headings, heading word, 
drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
27,735 
 
3 1 or 2 23,4960 
 
4 retina macula lutea/ or macula*.mp.  57,065 
 
5 3 and 4 13,297 
 
6 macular edema.mp. or retina macula edema/ 10,492 
 
7 macular oedema.mp. 1,441 
 
8 5 or 6 or 7 13,297 
 
9 diabetes mellitus/or diabet*.mp. 722,041 
 
10 8 and 9  5,351 
 
11 diabetic macular edema/ 2,040 
 
12 10 or 11 5,351 
 
13 vitrectomy.mp. or vitrectomy/ 18,637 
 
14 12 and 13 950 
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Appendix 2. PRISMA 2009 Flow Diagram (Efficacy Analysis) 
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Appendix 3. Risk of Bias Summary of Included Studies 
Study:  Kumar 2007 
Methods 
Randomized controlled trial 
Participants 24 Eyes. Visual acuity ≤ 6/60, diffuse macular edema, HbA1C > 7.5%, study 
based in India. 
Excluded patients with fundus fluorescein angiogram (FFA) evidence of 
macular ischemia, vitreomacular traction, cataract surgery within 1 year, 
previous vitrectomy, previous panretinal photocoagulation (PRP) in 
12months, previous grid laser in 6 months, uncontrolled diabetes, 
hypertension or chronic renal failure 
Interventions Pars plana vitrectomy (PPV) with dye-assisted internal limiting membrane 
(ILM) peel or grid LASER. No triamcinolone used 
Outcomes Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA), 
macular thickness, macular volume at 6 months 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Unclear 
Randomisation method not mentioned 
Allocation concealment 
(selection bias) 
Unclear Randomisation concealed by sealed 
envelop 
Blinding of participants and 
personnel (performance bias) 
High risk Patients not masked (vitrectomy or 
laser) 
Blinding of outcome 
assessment (detection bias) 
Unclear 
No mention if assessors were masked 
Incomplete outcome data 
(attrition bias) 
Low risk 
25 patients assessed, 24 eyes analysed 
Selective reporting (reporting 
bias) 
Low risk 
All outcomes reported 
Other bias Low risk  
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Study: Patel 2006 
Methods 
Randomized controlled trial 
Participants 20 patients recruited, 7 vitrectomy patients, 8 laser patients 
Clinically significant macular edema (CSME) depsite previous macular laser 
(less than 2years), Snellen acuity 6/15- 6/60 (65- 35 letters) 
Excluded macular ischemia 
Interventions 
Vitrectomy (ILM not peeled) (7 patients) or macular laser (8 patients) 
Outcomes ETDRS VA, optical coherence tomography (OCT), and FFA at baseline and 
12 months 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Low risk Randomisation performed by separate 
department in same hospital. 
Comment: Probably done 
Allocation concealment 
(selection bias) 
High risk 
Concealment method not described 
Blinding of participants and 
personnel (performance bias) 
High risk 
Patients can not be masked to 
intervention 
Blinding of outcome 
assessment (detection bias) 
Low risk 
Masked observers 
Incomplete outcome data 
(attrition bias) 
Low risk 
20 patients recruited, 15 analysed- 
similar attrition in each group 
Selective reporting (reporting 
bias) 
Low risk 
All outcomes reported 
Other bias Low risk  
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Study: Thomas 2005 
Methods 
Randomized controlled trial 
Participants Diabetic macular edema with no macular traction 
Previous macular laser 
VA 6/12 or worse 
Excluded ischemic maculopathy 
Interventions 19 patients randomised to vitrectomy with ILM peel compared to 21 
control patients undergoing further macular laser 
Outcomes Best corrected logarithm of the minimum angle of resolution (LogMAR) VA 
and mean OCT central macular thickness 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
Low risk 
Randomization prepared by 
independent medical statistician 
Allocation concealment 
(selection bias) 
Low risk 
Sealed, numbered opaque envelopes 
used: probably adequate 
Blinding of participants and 
personnel (performance bias) 
High risk 
Unable to mask patients 
Blinding of outcome 
assessment (detection bias) 
Unclear 
risk No mention if assessors were masked 
Incomplete outcome data 
(attrition bias) 
Low risk Similar loss to follow up in both groups 
(vitrectomy group loss 4/19, laser 
control group loss 3/18) 
Selective reporting (reporting 
bias) 
Low risk All outcomes reported 
Intention to treat analysis used 
Other bias Low risk  
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Study: Yanyali 2005 
Methods 
Randomised controlled trial 
Participants 12 patients, 24 eyes 
Bilateral diabetic macular edema 
Type 2 diabetes 
No vitreomacular traction 
No previous laser 
Interventions 12 eyes vitrectomy with ILM peeling 
Fellow 12 eyes undergo macular laser 
Outcomes 
Best corrected LogMAR VA and mean OCT central macular thickness 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
High risk 
Method of randomisation not explained 
Allocation concealment 
(selection bias) 
High risk 
Method of concealment not explained 
Blinding of participants and 
personnel (performance bias) 
High risk 
Participant not masked 
Blinding of outcome 
assessment (detection bias) 
Unclear 
risk No mention if assessors were masked 
Incomplete outcome data 
(attrition bias) 
Low risk 
Full follow up 
Selective reporting (reporting 
bias) 
Low risk 
All outcomes reported 
Other bias Low risk  
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Study: Yanyali 2006 
Methods 
Randomized controlled trial 
Participants 10 patients, 20 eyes 
Bilateral diabetic macula edema 
Type 2 diabetes 
All had previous grid laser and now considered 'unresponsive to further 
laser' 
No vitreomacular traction 
Interventions 10 eyes underwent vitrectomy with ILM peeling 
10 fellow eyes followed observation alone 
Outcomes 
OCT retinal thickness and visual acuity 
 
Bias 
Authors 
judgement 
Support for judgement 
Random sequence generation 
(selection bias) 
High risk 
Method of randomization not explained 
Allocation concealment 
(selection bias) 
High risk 
Method of concealment not explained 
Blinding of participants and 
personnel (performance bias) 
High risk 
Unable to mask patients 
Blinding of outcome 
assessment (detection bias) 
Low risk 
Assessor was masked to treatment 
groups 
Incomplete outcome data 
(attrition bias) 
Low risk 
No patients lost to follow up 
Selective reporting (reporting 
bias) 
Low risk 
All outcomes reported 
Other bias Low risk  
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Appendix 4. PRISMA 2009 Flow Diagram (Safety Analysis). 
 
 
 
Records identified through 
database searching 
(n =  425) 
Sc
re
en
in
g 
In
cl
u
d
e
d
 
El
ig
ib
ili
ty
 
Id
e
n
ti
fi
ca
ti
o
n
 
Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 425) 
Records screened 
(n = 425) 
Records excluded 
(n = 319) 
Full-text articles assessed 
for eligibility 
(n = 106) 
Full-text articles excluded 
(n =  59: no data on safety 
available) 
Studies included in 
qualitative synthesis 
(n = 40) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 40) 
